Anaptysbio, Inc financial data

Symbol
ANAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
10770 Wateridge Circle, Suite 210, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ANAPTYS BIOSCIENCES INC (to 11/20/2007)
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05K % -26%
Return On Equity -256 % -290%
Return On Assets -38.4 % -53.1%
Operating Margin -533 % +50.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.4M shares +3.4%
Common Stock, Shares, Outstanding 27.4M shares +3.41%
Entity Public Float 367M USD -8.45%
Common Stock, Value, Issued 27K USD 0%
Weighted Average Number of Shares Outstanding, Basic 27.4M shares +2.73%
Weighted Average Number of Shares Outstanding, Diluted 27.4M shares +2.73%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 30.5M USD +136%
Research and Development Expense 42M USD +27.6%
General and Administrative Expense 42.1M USD +5.82%
Operating Income (Loss) -162M USD -15.9%
Nonoperating Income (Expense) -7.72M USD -101%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -46.7M USD -17.1%
Income Tax Expense (Benefit) 9K USD
Net Income (Loss) Attributable to Parent -170M USD -18.1%
Earnings Per Share, Basic -6.35 USD/shares -22.4%
Earnings Per Share, Diluted -6.35 USD/shares -22.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.8M USD +104%
Assets, Current 367M USD -16.2%
Property, Plant and Equipment, Net 1.83M USD -9.39%
Operating Lease, Right-of-Use Asset 15.3M USD -10.3%
Other Assets, Noncurrent 256K USD 0%
Assets 427M USD -17.4%
Accounts Payable, Current 4.89M USD +2.71%
Employee-related Liabilities, Current 5.42M USD +34%
Accrued Liabilities, Current 33.7M USD -4.22%
Liabilities, Current 40.4M USD -2.91%
Operating Lease, Liability, Noncurrent 15.1M USD -10.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -415K USD +88.5%
Retained Earnings (Accumulated Deficit) -705M USD -31.8%
Stockholders' Equity Attributable to Parent 9.88M USD -93.3%
Liabilities and Equity 427M USD -17.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD -51.6%
Net Cash Provided by (Used in) Financing Activities -13.6M USD +63.7%
Net Cash Provided by (Used in) Investing Activities 68.6M USD -19.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.4M shares +3.41%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17.7M USD -23.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 71.8M USD +104%
Deferred Tax Assets, Valuation Allowance 151M USD +29.9%
Deferred Tax Assets, Gross 158M USD +30.7%
Operating Lease, Liability 16.9M USD -9.15%
Payments to Acquire Property, Plant, and Equipment 27K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -167M USD -16.1%
Lessee, Operating Lease, Liability, to be Paid 19.6M USD -11%
Property, Plant and Equipment, Gross 8.35M USD +5.27%
Operating Lease, Liability, Current 1.85M USD +8.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.61M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.53M USD +3.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.67M USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.69M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 72.8M USD +10%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 5.02M USD +48.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.77M USD +3.02%
Operating Lease, Payments 602K USD +2.91%
Additional Paid in Capital 715M USD +4.13%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 163K USD -1.81%
Share-based Payment Arrangement, Expense 7.54M USD -10.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%